Tuberculous meningitis is often lethal. Early antituberculosis treatment and adjunctive treatment with glucocorticoids improve survival, but nearly one third of patients with the condition still die. ...We hypothesized that intensified antituberculosis treatment would enhance the killing of intracerebral Mycobacterium tuberculosis organisms and decrease the rate of death among patients.
We performed a randomized, double-blind, placebo-controlled trial involving human immunodeficiency virus (HIV)-infected adults and HIV-uninfected adults with a clinical diagnosis of tuberculous meningitis who were admitted to one of two Vietnamese hospitals. We compared a standard, 9-month antituberculosis regimen (which included 10 mg of rifampin per kilogram of body weight per day) with an intensified regimen that included higher-dose rifampin (15 mg per kilogram per day) and levofloxacin (20 mg per kilogram per day) for the first 8 weeks of treatment. The primary outcome was death by 9 months after randomization.
A total of 817 patients (349 of whom were HIV-infected) were enrolled; 409 were randomly assigned to receive the standard regimen, and 408 were assigned to receive intensified treatment. During the 9 months of follow-up, 113 patients in the intensified-treatment group and 114 patients in the standard-treatment group died (hazard ratio, 0.94; 95% confidence interval, 0.73 to 1.22; P=0.66). There was no evidence of a significant differential effect of intensified treatment in the overall population or in any of the subgroups, with the possible exception of patients infected with isoniazid-resistant M. tuberculosis. There were also no significant differences in secondary outcomes between the treatment groups. The overall number of adverse events leading to treatment interruption did not differ significantly between the treatment groups (64 events in the standard-treatment group and 95 events in the intensified-treatment group, P=0.08).
Intensified antituberculosis treatment was not associated with a higher rate of survival among patients with tuberculous meningitis than standard treatment. (Funded by the Wellcome Trust and the Li Ka Shing Foundation; Current Controlled Trials number, ISRCTN61649292.).
This study investigated methyl orange (MO) dye adsorption using three biochars produced from agro-waste and invasive plants; the latter consisted of wattle bark (BA), mimosa (BM), and coffee husks ...(BC). BC had the lowest specific surface area (2.62 m2/g) compared to BA (393.15 m2/g) and BM (285.53 m2/g). The adsorption efficiency of MO was stable at pH 2–7 (95%–96%), whilst it had reduced stability at pH 7–12. Between 0 and 30 min, MO adsorption efficiency was >82%, and at 120 min, representative adsorption equilibrium had occurred. The maximum adsorption capacity of the biochars was 12.3 mg/g. The underlying adsorption mechanisms of the three biochars were governed by electrostatic adsorption and pore diffusion. There was an abundance of active sites for adsorption in BA and BM, while chemical adsorption appeared to be more vital for BC, as it contained more functional groups on its surface. The highest MO adsorption efficiency occurred with BM. BC was not recommended for MO removal, as it was observed to stain the water when a dose exceeding 5.0 g/L was utilized.
Display omitted
•Biochars were successfully derived from agro-waste and invasive plants.•After only 30 min the methyl orange adsorption efficiency on biochar was more than 82%.•The adsorption equilibrium was established at 120 min.•The highest adsorption occurred with biochar from mimosa.
There are few data on long-term mortality following osteoporotic fracture and fewer following subsequent fracture.
To examine long-term mortality risk in women and men following all osteoporotic ...fractures and to assess the association of subsequent fracture with that risk.
Prospective cohort from the Dubbo Osteoporosis Epidemiology Study of community-dwelling women and men aged 60 years and older from Dubbo, Australia, who sustained a fracture between April 1989 and May 2007.
Age- and sex-specific standardized mortality ratios (SMRs) compared with the overall Dubbo population for hip, vertebral, major, and minor fractures.
In women, there were 952 low-trauma fractures followed by 461 deaths, and in men, 343 fractures were followed by 197 deaths. Age-adjusted SMRs were increased following hip fractures (SMRs, 2.43 95% confidence interval CI, 2.02-2.93 and 3.51 95% CI, 2.65-4.66), vertebral fractures (SMRs, 1.82 95% CI, 1.52-2.17 and 2.12 95% CI, 1.66-2.72), major fractures (SMRs, 1.65 95% CI, 1.31-2.08 and 1.70 95% CI, 1.23-2.36), and minor fractures (SMRs, 1.42 95% CI, 1.19-1.70 and 1.33 95% CI, 0.99-1.80) for both women and men, respectively. Mortality was increased for all ages for all fractures except minor fractures for which increased mortality was only apparent for those older than 75 years. Increased mortality risk persisted for 5 years for all fractures and up to 10 years for hip fractures. Increases in absolute mortality that were above expected, for 5 years after fracture, ranged from 1.3 to 13.2 per 100 person-years in women and from 2.7 to 22.3 per 100 person-years in men, depending on fracture type. Subsequent fracture was associated with an increased mortality hazard ratio of 1.91 (95% CI, 1.54-2.37) in women and 2.99 (95% CI, 2.11-4.24) in men. Mortality risk following a subsequent fracture then declined but beyond 5 years still remained higher than in the general population (SMR, 1.41 95% CI, 1.01-1.97 and SMR, 1.78 95% CI, 0.96-3.31 for women and men, respectively). Predictors of mortality after any fragility fracture for both men and women included age, quadriceps weakness, and subsequent fracture but not comorbidities. Low bone mineral density, having smoked, and sway were also predictors for women and less physical activity for men.
In a sample of older women and men, all low-trauma fractures were associated with increased mortality risk for 5 to 10 years. Subsequent fracture was associated with increased mortality risk for an additional 5 years.
Our study investigated magnetic resonance imaging measurements for differentiating cerebellopontine angle (CPA) meningioma from vestibular schwannoma (VS).
This retrospective study compared 36 ...meningioma and 36 VS patients. The tumor volume (Vtumor) and peritumor edema index (EI) relationship was analyzed. T2-weighted three-dimensional gradient-echo image signal intensity (T23D) and apparent diffusion coefficient (ADC) differentiation cutoff values were defined. Mann-Whitney U test, independent-samples t-test, receiver operating characteristic curve, and Spearman's correlation analyses were applied.
Meningioma had higher Vtumor (p=0.009) and EI (p=0.031) values than VS. Meningioma had significantly (p<0.001) lower values than VS for mean ADC (ADCmean: 0.841±0.083×10-3 vs.1.173±0.190×10-3 mm2/s), minimum ADC (ADCmin: 0.716±0.078×10-3 vs.1.045±0.178×10-3 mm2/s), tumor:white matter ADC ratio (rADC: 1.198±0.19 vs. 1.59±0.30), mean T23D (T23Dmean: 142.91±19.9 vs. 218.72±84.73), and tumor:adipose T23D ratio (rT23d: 0.19±0.06 vs. 0.30±0.28) Cutoff, sensitivity (Se), and specificity (Sp) values were ADCmin, 0.856×10-3 mm2/s (Se: 96.6%, Sp: 100%); ADCmean, 0.963×10-3 mm2/s (Se: 96.6%, Sp: 95.5%); rADC, 1.3189 (Se: 93.1%, Sp: 81.8%), T23Dmean (Se: 96.6%, Sp: 100%); rT23D, 0.1951 (Se: 89.7%, Sp: 100%), Vtumor, 14828.65 mm3 (Se: 75.0%, Sp: 66.7%), and EI, 1.1025 (Se: 47.2%, Sp: 100%).
ADCmin, ADCmean, rADC, T23Dmean, rT23D, Vtumor, and EI, effectively discriminated meningioma from VS.
Adjunctive glucocorticoids are widely used to treat human immunodeficiency virus (HIV)-associated tuberculous meningitis despite limited data supporting their safety and efficacy.
We conducted a ...double-blind, randomized, placebo-controlled trial involving HIV-positive adults (≥18 years of age) with tuberculous meningitis in Vietnam and Indonesia. Participants were randomly assigned to receive a 6-to-8-week tapering course of either dexamethasone or placebo in addition to 12 months of antituberculosis chemotherapy. The primary end point was death from any cause during the 12 months after randomization.
A total of 520 adults were randomly assigned to receive either dexamethasone (263 participants) or placebo (257 participants). The median age was 36 years; 255 of 520 participants (49.0%) had never received antiretroviral therapy, and 251 of 484 participants (51.9%) with available data had a baseline CD4 count of 50 cells per cubic millimeter or less. Six participants withdrew from the trial, and five were lost to follow-up. During the 12 months of follow-up, death occurred in 116 of 263 participants (44.1%) in the dexamethasone group and in 126 of 257 participants (49.0%) in the placebo group (hazard ratio, 0.85; 95% confidence interval, 0.66 to 1.10; P = 0.22). Prespecified analyses did not reveal a subgroup that clearly benefited from dexamethasone. The incidence of secondary end-point events, including cases of immune reconstitution inflammatory syndrome during the first 6 months, was similar in the two trial groups. The numbers of participants with at least one serious adverse event were similar in the dexamethasone group (192 of 263 participants 73.0%) and the placebo group (194 of 257 participants 75.5%) (P = 0.52).
Among HIV-positive adults with tuberculous meningitis, adjunctive dexamethasone, as compared with placebo, did not confer a benefit with respect to survival or any secondary end point. (Funded by the Wellcome Trust; ACT HIV ClinicalTrials.gov number, NCT03092817.).
We report herein investigation on crystallization of amorphous molybdenum sulfide a-MoS x induced by electron and laser beam resulting in formation of crystalline molybdenum disulfide c-MoS2. This ...crystallization occurred in situ during transmission electron microscopic and Raman analyses of a-MoS x material. It was also found that a-MoS x to c-MoS2 phase transformation was not fully beneficial for H2-evolving catalytic performance. c-MoS2 showed better robustness but significantly lower catalytic performance. Furthermore, c-MoS2 was less tolerant to oxidation stress, as the one caused by photogenerated holes within the light harvester, compared with a-MoS x catalyst. Thus, a-MoS x is a better candidate for implementation within photocatalysts for overall solar water-splitting application.
Significant long-term mortality reduction was demonstrated in women with and without fractures taking oral bisphosphonates, compared to no therapy.
Context:
Osteoporotic fractures are associated with ...premature mortality. Antiresorptive treatment reduces refracture but mortality reduction is unclear.
Objective:
The objective of the study was to examine the effect of osteoporosis treatment bisphosphonates (BP), hormone therapy (HT), and calcium ± vitamin D only (CaD) on mortality risk.
Design:
This was a prospective cohort study (April 1989 to May 2007).
Setting:
The study was conducted with community-dwelling elderly (aged 60+ yr) subjects in Dubbo, a semiurban city, Australia.
Subjects:
Subjects included 1223 and 819 women and men in the Dubbo Osteoporosis Epidemiology Study.
Main Outcome Measure:
Mortality according to treatment group was recorded.
Results:
There were 325 (BP, n = 106; HT, n = 77; CaD, n = 142) women and 37 men (BP, n = 15; CaD, n = 22) on treatment. In women, mortality rates were lower with BP 0.8/100 person-years (0.4, 1.4) and HT 1.2/100 person-years (0.7, 2.1) but not CaD 3.2/100 person-years (2.5, 4.1) vs. no treatment 3.5/100 person-years (3.1, 3.8). Accounting for age, fracture occurrence, comorbidities, quadriceps strength, and bone mineral density, mortality risk remained lower for women on BP hazard ratio (HR) 0.3 (0.2, 0.6) but not HT HR 0.8 (0.4, 1.8). For 429 women with fractures, mortality risk was still reduced in the BP group adjusted HR 0.3 (0.2, 0.7), not accounted for by a reduction in subsequent fractures. In men, lower mortality rates were observed with BP but not CaD BP 1.0/100 person-years (0.3, 3.9) and CaD 3.1/100 person-years (1.5, 6.6) vs. no treatment 4.3/100 person-years (3.9, 4.8). After adjustment, mortality was similar, although not significant HR 0.5 (0.1, 2.0).
Conclusions:
Osteoporosis therapy appears to reduce mortality risk in women and possibly men.
In this study, activated carbon in the form of carbonaceous hydrochar adsorbents with highly functionalized surface-active sites were produced from coffee husk waste via hydrothermal carbonization ...under low-temperature conditions (180 °C) and subsequent chemical activation. Thereafter, the hydrochars were characterized using diverse analytical techniques, and batch experiments of methylene blue (MB) adsorption were performed under various operating conditions. The results indicated that the activated hydrochar (AH) had a larger specific surface area (862.2 m2 g−1) compared to that of its carbonaceous precursor (33.7 m2 g−1). The maximum MB sorption capacity of the hydrochar activated with potassium hydroxide was extremely high (415.8 mg g−1 at 30 °C). In addition, adsorption isotherms and kinetics were studied using experimental data fitting to further understand and describe the dynamic equilibrium, dynamic kinetics, and mechanism of MB adsorption onto the prepared hydrochars. As compared to the Freundlich isotherm model, the Langmuir isotherm model provided a better fit with the experimental data exhibiting a maximum monolayer adsorption capacity of 418.78 mg g−1. The linear pseudo-second-order kinetic model was found to be suitable for describing the adsorptive kinetics of the hydrochar. The results demonstrated the immense potential of coffee husk waste to produce activated carbon as an alternative green hydrochar that can be applied to dye removal from wastewater as well as improvement of waste management.
Display omitted
•High-performance activated hydrochar (AH) was derived from coffee husks and tested.•AH had an excellent specific surface area of 862.2 m2 g−1.•Derived AH efficiently removed methylene blue (MB) dye.•The highest MB removal (415.8 mg g−1) was achieved under experimental conditions.•Adsorption isotherm and kinetic studies were conducted by experimental data fitting.
Adsorption in the continuous mode plays a significant role in wastewater treatment. In this study, Mimosa pigra-derived biochar modified with 2 M AlCl3 salt was used to pack a lab-scale column to ...eliminate PO43− from aqueous solutions. The influence of the operational factors, such as inlet PO43− concentration (25–100 mg/L), flow rate (6–18 mL/min), and biochar bed height (1.5–4.5 cm), on the breakthrough curve was evaluated. The kinetic models of Adam–Bohart and Yoon–Nelson were utilized to analyze the experimental results. The best conditions were determined to be the influent PO43− strength of 50 mg/L, injection speed of 6 mL/min, and column height of 4.5 cm. These results can be applied in the design of large-scale columns for the sequestration of PO43− from wastewater.
Display omitted
•Phosphate was successfully removed using fixed-bed modified biochar column.•The inlet PO43−, flow rate, and bed height affected the breakthrough curve.•The optimal conditions were 50 mg/L of PO43−, 6 mL/min flow rate, and 4.5 cm height.•Adam–Bohart and Yoon–Nelson models were utilized to describe experimental results.
PDF
